KR840006437A - 항생제 경구 투여용 제형의 제조방법 - Google Patents
항생제 경구 투여용 제형의 제조방법 Download PDFInfo
- Publication number
- KR840006437A KR840006437A KR1019830004866A KR830004866A KR840006437A KR 840006437 A KR840006437 A KR 840006437A KR 1019830004866 A KR1019830004866 A KR 1019830004866A KR 830004866 A KR830004866 A KR 830004866A KR 840006437 A KR840006437 A KR 840006437A
- Authority
- KR
- South Korea
- Prior art keywords
- fatty acids
- mixture
- product
- mono
- enhancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 14
- 238000009472 formulation Methods 0.000 title 1
- 229940127249 oral antibiotic Drugs 0.000 title 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 8
- 239000002132 β-lactam antibiotic Substances 0.000 claims 8
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 8
- 239000003623 enhancer Substances 0.000 claims 7
- 125000005456 glyceride group Chemical group 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 150000004665 fatty acids Chemical class 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004755 ceftriaxone Drugs 0.000 claims 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- -1 fatty acids monoglycerides Chemical class 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 229940024554 amdinocillin Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229960000433 latamoxef Drugs 0.000 claims 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims 1
- 229960000198 mezlocillin Drugs 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 235000010935 mono and diglycerides of fatty acids Nutrition 0.000 claims 1
- 229940056360 penicillin g Drugs 0.000 claims 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (16)
- 항생제를, 지방족 C2-C18지방산, C2-C12지방산으 모노글리세라이드, 디글리세라이드 및 트리글리세라이드, C2-C12지방상과프로필렌글리콜, 폴리에틸렌글리콜 및 탄수화물의 부분 및 전체 에스테르, 그들의 약학적으로 허용된 에스테르 및 에테르 및 언급된 증진제들의 혼합물 등으로부터 선택된 증진제의 흡수 증진량과 혼합하고, 경우에 따라서는 혼합 생성물을 약학적으로 허용되는 담체와 혼합시킴을 특징으로 하여 실제적으로 경구 비활성인 β-락탐 항생제로부터 장내투여시 활성인 생성물을 제조하는 방법.
- 제1항에 있어서, 혼합생성물을 장용피 형태로 변형시킴으로써 경구 활성인 생성물로 전환시키는 방법.
- 제1항에 있어서, β-락탐 항생제와 지방산 또는 글리세라이드 또는 그들의 혼합물을 용액 또는 현탁제로 혼합시키는 방법
- 제1항 또는 2항에 있어서, β-락탐 항생제와 지방산 또는 글리세라이드 또는 그들의 혼합물을 고체혼합물로 혼합시키는 방법
- 제1항 내지 4항중 어느 한 항에 있어서, 증진제로서 글리세라이드, 또는 모노글리세라이드, 성분이 다량 함유된, 지방산의 모노- 및 디글리세라이드의 혼합물을 사용하는 방법.
- 제1항 내지 5항중 어느 한 항에 있어서, 생성물이, β-락탐 항생제가 약 25mg 내지 약 2000mg의 양으로 함유된 투여형태로 제조되는 방법.
- 제6항에 있어서, β-락탐 항생제가 약 50 내지 약 500mg의 양으로 사용된 방법.
- 제1항 내지 7항중 어느 한 항에 있어서, 증진제로서 C8-C12지방산의 글리세라이드 혼합물이 사용된 방법.
- 제1항 내지 8항중 어느 한 항에 있어서, 증진제로서 글리세라이드 혼합물이 조성물 중량의 약 33% 내지 약 98%로 사용된 방법.
- 제9항에 있어서, 글리세라이드 혼합물이 조성물 중량의 약 89%로 사용된 방법.
- 제1항 내지 10항중 어느 한 항에 있어서, 생성물이 장용피깝셀, 마이크로깝셀 또는 비드렛(beadlet)과 같은 투여형태로 제조되는 방법.
- 제1항, 2항 및 4항 내지 10항중 어느 한 항에 있어서, 생성물이 정제와 같은 투여 형태로 제조되는 방법.
- 제1항 내지 12항중 어느 한 항에 있어서, 증진제로서, 모노글리세라이드가 모노/디글리세라이드 혼합물의 약 70% 또는 약 90%로 존재하는 C8/C10포화 지방산의 모노- 및 디글리세라이드의 혼합물을 사용하는 방법.
- 제1항 내지 13항 중 어느 한 항에 있어서, 세프트리악손이 β-락탐 항생제로 사용된 방법.
- 제1항 내지 13항중 어느 한 항에 있어서, β-락탐 항생제가 세폭시틴, 티에나마이신, 아즈트레오남, 목살락탐, 세팔로친, 세파만돌, 세포탁심, 세포페라존, 메즈로실린, 피페라실린,세파졸린, 암디노실린 및 페니실린 G로부터 선택된 방법.
- 제1항 내지 14항중 어느 한 항에 있어서, 세프트리악손이 β-락탐 항생제로 사용되고, 증진제로서는 모노글리세라이드가 모노/디글리세라이드 혼합물의 약 70% 또는 약 90%로 존재하는 C8/C10포화지방산의 모노- 및 디글리세라이드 혼합물이 사용된 방법.※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US434452 | 1982-10-15 | ||
| US06/434,452 US4525339A (en) | 1982-10-15 | 1982-10-15 | Enteric coated oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR840006437A true KR840006437A (ko) | 1984-11-30 |
Family
ID=23724297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019830004866A KR840006437A (ko) | 1982-10-15 | 1983-10-14 | 항생제 경구 투여용 제형의 제조방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4525339A (ko) |
| EP (1) | EP0108295A1 (ko) |
| JP (1) | JPS59104312A (ko) |
| KR (1) | KR840006437A (ko) |
| AU (1) | AU2019283A (ko) |
| DK (1) | DK473183A (ko) |
| FI (1) | FI833728A (ko) |
| GR (1) | GR82301B (ko) |
| IL (1) | IL69960A0 (ko) |
| MC (1) | MC1550A1 (ko) |
| NO (1) | NO833757L (ko) |
| PT (1) | PT77503A (ko) |
| ZA (1) | ZA837307B (ko) |
| ZW (1) | ZW22183A1 (ko) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60146825A (ja) * | 1984-01-10 | 1985-08-02 | Asahi Chem Ind Co Ltd | 経口医薬製剤 |
| CA1256799A (en) * | 1984-02-22 | 1989-07-04 | Walter Fuller | Suppositories |
| US4760059A (en) * | 1985-08-05 | 1988-07-26 | Hoffmann-La Roche Inc. | Rectal dosage form |
| IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
| SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
| JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| EP0281200B1 (en) * | 1987-03-02 | 1994-01-19 | Yamanouchi Europe B.V. | Pharmaceutical composition, pharmaceutical granulate and process for their preparation |
| KR880012221A (ko) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 |
| IE59934B1 (en) * | 1987-06-19 | 1994-05-04 | Elan Corp Plc | Liquid suspension for oral administration |
| DE3729299A1 (de) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | Transdermales therapeutisches system |
| US5009894A (en) * | 1988-03-07 | 1991-04-23 | Baker Cummins Pharmaceuticals, Inc. | Arrangement for and method of administering a pharmaceutical preparation |
| US5260271A (en) * | 1988-06-22 | 1993-11-09 | Applied Microbiology, Inc. | Nisin compositions for use as enhanced broad range bactericides |
| US4925674A (en) * | 1988-08-25 | 1990-05-15 | Himedics, Inc. | Amoxicillin microencapsulated granules |
| US5190748A (en) * | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| ZA898331B (en) * | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
| ZA906186B (en) * | 1989-09-11 | 1991-06-26 | Hoffmann La Roche | Pharmaceutical preparations |
| US6482516B1 (en) * | 1993-07-20 | 2002-11-19 | Banner Pharmacaps, Inc. | Enrobed tablet |
| AT393955B (de) * | 1990-03-30 | 1992-01-10 | Martin Dr Leixnering | Einrichtung zur nachbehandlung frischer beugesehnenverletzungen |
| US5342612A (en) * | 1991-12-20 | 1994-08-30 | American Cyanamid Company | Compositions for the treatment of mammalian diseases |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| US5382435A (en) * | 1993-03-24 | 1995-01-17 | Southwest Research Institute | Microparticulate pharmaceutical delivery system |
| US5318781A (en) * | 1993-04-06 | 1994-06-07 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| US5559110A (en) * | 1994-03-09 | 1996-09-24 | The Dupont Merck Pharmaceutical Company | Pharmaceutical formulations of cyclic urea type compounds |
| US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
| GB9407386D0 (en) | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| DE723436T1 (de) * | 1994-07-08 | 1997-09-11 | Astra Ab | Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i) |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| SE9600072D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| ATE386508T1 (de) * | 1999-02-22 | 2008-03-15 | Merrion Res I Ltd | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| AU2001267011B2 (en) | 2000-06-21 | 2006-02-02 | Cubist Pharmaceuticals, Inc. | Compositions and methods to improve the oral absorption of antimicrobial agents |
| US6248360B1 (en) | 2000-06-21 | 2001-06-19 | International Health Management Associates, Inc. | Complexes to improve oral absorption of poorly absorbable antibiotics |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US20030175350A1 (en) * | 2000-07-11 | 2003-09-18 | Katsuji Sugita | Enteric preparations containing physiologically active peptides |
| US7820722B2 (en) * | 2001-05-11 | 2010-10-26 | Merrion Research Iii Limited | Permeation enhancers |
| CA2446622C (en) * | 2001-05-11 | 2012-08-14 | Elan Corporation, Plc | Isostearic acid salts as permeation enhancers |
| KR100540035B1 (ko) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| US8501232B2 (en) * | 2002-04-23 | 2013-08-06 | Nanotherapeutics, Inc. | Process of forming and modifying particles and compositions produced thereby |
| TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
| US20050152969A1 (en) * | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
| AU2006242535B2 (en) * | 2005-04-29 | 2012-08-09 | Merck Sharp & Dohme Corp. | Therapeutic compositions |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2007146234A2 (en) * | 2006-06-09 | 2007-12-21 | Merrion Research Ii Limited | Solid oral dosage form containing an enhancer |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| WO2009032246A2 (en) | 2007-09-03 | 2009-03-12 | Nanotherapeutics, Inc. | Particulate compositions for delivery of poorly soluble drugs |
| CA2702935A1 (en) * | 2007-10-19 | 2009-04-23 | Purdue Research Foundation | Solid formulations of crystalline compounds |
| EP2288368A1 (en) * | 2008-05-07 | 2011-03-02 | Merrion Research III Limited | Compositions of peptides and processes of preparation thereof |
| JP2012518686A (ja) * | 2009-02-25 | 2012-08-16 | メリオン・リサーチ・Ｉｉｉ・リミテッド | ビスホスホネート類の組成物および薬物送達 |
| EP2512454A2 (en) | 2009-12-16 | 2012-10-24 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| CA2819234A1 (en) | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
| WO2013052010A1 (en) * | 2011-10-03 | 2013-04-11 | Agency For Science, Technology And Research | Antibiotic composition and its uses |
| WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
| WO2019036770A1 (en) * | 2017-08-24 | 2019-02-28 | University Of South Australia | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE567598A (ko) * | ||||
| US2476351A (en) * | 1945-06-07 | 1949-07-19 | Parke Davis & Co | Injectable penicillin compositions |
| US2487336A (en) * | 1946-02-25 | 1949-11-08 | William E Hinds | Penicillin product |
| US2443778A (en) * | 1947-04-21 | 1948-06-22 | Monroe J Romansky | Preparations for penicillin therapy |
| US2566200A (en) * | 1947-06-07 | 1951-08-28 | Commercial Solvents Corp | Oral therapeutic tablets |
| US2507193A (en) * | 1949-05-17 | 1950-05-09 | Bristol Lab Inc | Penicillin product |
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| US2902407A (en) * | 1955-06-14 | 1959-09-01 | Commercial Solvents Corp | Wax-coated penicillin product |
| US2864744A (en) * | 1955-09-02 | 1958-12-16 | American Home Prod | Penicillin in solid dosage unit form |
| US3016330A (en) * | 1955-11-10 | 1962-01-09 | Novo Terapeutisk Labor As | Therapeutical antibiotic composition |
| US2951014A (en) * | 1957-01-03 | 1960-08-30 | Upjohn Co | Process for a stable oil suspension |
| US3402240A (en) * | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
| NL297631A (ko) * | 1963-06-03 | |||
| US3849569A (en) * | 1965-12-02 | 1974-11-19 | Glaxo Lab Ltd | Composition containing procaine penicillin |
| GB1226555A (ko) * | 1967-08-08 | 1971-03-31 | ||
| US3549746A (en) * | 1967-11-02 | 1970-12-22 | Bristol Myers Co | Antibiotic composition |
| US3626056A (en) * | 1967-11-02 | 1971-12-07 | Bristol Myers Co | Oral antibiotic product |
| US3538215A (en) * | 1969-06-13 | 1970-11-03 | Allied Chem | Stabilized antibiotic in liquid ruminant feed supplement |
| GB1312918A (en) * | 1969-07-08 | 1973-04-11 | Beecham Group Ltd | Veterinary treatment |
| US3696189A (en) * | 1970-05-18 | 1972-10-03 | Frank M Snyder | Stabilized antibiotic and method |
| US3655864A (en) * | 1970-09-21 | 1972-04-11 | Smith Kline French Lab | Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption |
| JPS4971127A (ko) * | 1972-11-18 | 1974-07-10 | ||
| GB1413186A (en) * | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
| US4145429A (en) * | 1974-09-21 | 1979-03-20 | Beecham Group Limited | Oral veterinary preparations |
| US3996355A (en) * | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
| GB1547164A (en) * | 1975-08-14 | 1979-06-06 | Beecham Group Ltd | Veterinary compositions |
| JPS5231981A (en) * | 1975-08-18 | 1977-03-10 | Takeda Chem Ind Ltd | Microcapsule preparation method |
| JPS5283924A (en) * | 1976-01-01 | 1977-07-13 | Sumitomo Chem Co Ltd | Preparation of pharmaceuticals for rectal infusion containing penicill ins and cephalosporins |
| JPS6055486B2 (ja) * | 1976-02-28 | 1985-12-05 | 富山化学工業株式会社 | β−ラクタム環を有する化合物の直腸投与用組成物 |
| JPS52139713A (en) * | 1976-05-13 | 1977-11-21 | Shionogi & Co Ltd | Sustained release cefalexin preparations |
| DE2654844A1 (de) * | 1976-12-03 | 1978-06-08 | Kali Chemie Pharma Gmbh | Verfahren zur herstellung fester loesungen von arzneistoffen zur oralen und rektalen applikation |
| US4250166A (en) * | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
| US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
| SE445174B (sv) * | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
| IL58462A0 (en) * | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a penicillin |
| GB2051574B (en) * | 1979-05-10 | 1984-01-18 | Kyoto Pharma Ind | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
| JPS56104812A (en) * | 1980-01-23 | 1981-08-20 | Sankyo Co Ltd | Production of cephalosporin compound preparation for rectal infusion |
| JPS5799519A (en) * | 1980-12-12 | 1982-06-21 | Toyo Jozo Co Ltd | Stable suppository and its preparation |
-
1982
- 1982-10-15 US US06/434,452 patent/US4525339A/en not_active Expired - Fee Related
-
1983
- 1983-09-29 ZA ZA837307A patent/ZA837307B/xx unknown
- 1983-10-13 ZW ZW221/83A patent/ZW22183A1/xx unknown
- 1983-10-13 DK DK473183A patent/DK473183A/da not_active Application Discontinuation
- 1983-10-13 IL IL69960A patent/IL69960A0/xx unknown
- 1983-10-13 FI FI833728A patent/FI833728A/fi not_active Application Discontinuation
- 1983-10-13 GR GR72682A patent/GR82301B/el unknown
- 1983-10-14 PT PT77503A patent/PT77503A/pt unknown
- 1983-10-14 NO NO833757A patent/NO833757L/no unknown
- 1983-10-14 AU AU20192/83A patent/AU2019283A/en not_active Abandoned
- 1983-10-14 KR KR1019830004866A patent/KR840006437A/ko not_active Application Discontinuation
- 1983-10-14 JP JP58191101A patent/JPS59104312A/ja active Pending
- 1983-10-14 MC MC831659A patent/MC1550A1/xx unknown
- 1983-10-17 EP EP83110343A patent/EP0108295A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL69960A0 (en) | 1984-01-31 |
| US4525339A (en) | 1985-06-25 |
| EP0108295A1 (de) | 1984-05-16 |
| PT77503A (en) | 1983-11-01 |
| ZA837307B (en) | 1984-06-27 |
| MC1550A1 (fr) | 1984-08-31 |
| ZW22183A1 (en) | 1985-04-17 |
| DK473183D0 (da) | 1983-10-13 |
| GR82301B (ko) | 1984-12-13 |
| DK473183A (da) | 1984-04-16 |
| JPS59104312A (ja) | 1984-06-16 |
| FI833728A0 (fi) | 1983-10-13 |
| AU2019283A (en) | 1984-04-19 |
| NO833757L (no) | 1984-04-16 |
| FI833728A (fi) | 1984-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR840006437A (ko) | 항생제 경구 투여용 제형의 제조방법 | |
| KR850000975A (ko) | 발프로익산과 그 염의 혼합물을 토대로 한 조성물 | |
| KR910014120A (ko) | 피모벤단의 경구용 약제학적 제제 | |
| PH17073A (en) | Prostaglandin composition | |
| JO2324B1 (en) | Pharmaceutical compounds for topical oral use | |
| JPS5350141A (en) | Stabilization of prostaglandin and prostaglandin analogues | |
| JPS5350316A (en) | Drug composition for oral administration | |
| JPS52806A (en) | Preparation of ester | |
| DE3462490D1 (en) | 5-aminosalicylic acid-0-sulfates of physiologically acceptable bases, process for their production and medicines containing them | |
| JPS5770815A (en) | Absorption improver | |
| DE2963545D1 (en) | Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation | |
| ES8306593A1 (es) | Procedimiento de preparar agentes farmaceuticos administra- bles por via topica | |
| JPS5668619A (en) | Nifedipine-containing solid composition | |
| JPS5731614A (en) | Lipid improver | |
| JPS5764609A (en) | Cyclophosphamide composition for rectal administration | |
| JPS5326316A (en) | Drug containing active vitamin d3 derivatives and its preparation | |
| RU2000108267A (ru) | Фармацевтические композиции на основе нестероидных противовоспалительных средств | |
| JPS5564755A (en) | Shortening for "baumkuchen" (germany cake) | |
| JPS56145223A (en) | Drug composition | |
| KR950703333A (ko) | 비이온계 계면활성제 함유 약학 조성물(Pharmaceutical Compositions Containing Nonionic Surfactants) | |
| JPS5484034A (en) | Anti-tumor agent | |
| JPS5686114A (en) | Pharmaceutical composition for suppository | |
| JPS5283413A (en) | Preparation of 3,3-dimethyl-4-pentenoic acid or its esters | |
| GB915815A (en) | Choleretic compositions comprising 1-phenyl-pentanol-(1) | |
| GB890638A (en) | Compositions for combating retinitis pigmentosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19831014 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |